Composites Based on Hydroxyapatite and Whey Protein Isolate for Applications in Bone Regeneration

Bone regeneration research has long focused on developing materials that can support skeletal repair while maintaining bioactivity. Hydroxyapatite is widely recognized for its bioactive properties, making it a popular choice for bone grafts. However, its brittleness limits mechanical performance, which is crucial in load-bearing applications. To address this limitation, researchers have explored combining HAp with polymers to improve strength and flexibility. While prior studies have demonstrated the benefits of polymer reinforcement, few have examined whey protein isolate as a matrix material. The need for a composite that retains bioactivity while enhancing mechanical properties remains a key challenge. This gap motivated investigations into organic-inorganic hydrogels as alternative bone substitutes. No prior work had resolved the full potential of WPI/HAp composites in this context. The question of how to optimize ceramic-polymer ratios for both function and bioactivity remains unresolved.

The aim of this research was to develop and evaluate hydrogel composites made from whey protein isolate reinforced with nano-hydroxyapatite. These materials were designed to address the brittleness of pure HAp while preserving its bioactive properties. The specific problem addressed was the need for a bone substitute that maintains mechanical strength and bioactivity. The motivation stemmed from the limitations of current materials in load-bearing applications. The researchers sought to determine if WPI could serve as an effective organic matrix for HAp. They also aimed to assess how varying HAp concentrations affect material properties. The study focused on physicochemical, mechanical, and biological performance of the composites. The ultimate goal was to identify a promising material for bone regeneration.

The study involved preparing hydrogel composites by mixing whey protein isolate with nano-hydroxyapatite powder in varying proportions. The ceramic content ranged from 0% to 15%. Physicochemical characterization was conducted using X-ray diffraction, Fourier-transform infrared spectroscopy, and scanning electron microscopy. Swelling capacity measurements were performed to assess hydrogel behavior in aqueous environments. Potentiometric and conductivity analyses were used to evaluate material stability and ionic interactions. In vitro tests were carried out in four fluids: distilled water, Ringer’s solution, artificial saliva, and simulated body fluid. Cytotoxicity was assessed using L-929 mouse fibroblasts according to ISO 10993-5:2009 standards. The effect of hydrogels on monocyte stimulation via NF-κB induction was also investigated.

The hydrogel composites showed successful integration of nano-HAp into the WPI matrix. XRD and FT-IR confirmed the presence of HAp and protein structures. SEM revealed a homogeneous dispersion of ceramic particles. Swelling capacity measurements indicated that higher HAp content reduced water uptake. Potentiometric and conductivity tests showed stable material behavior in simulated body fluids. In vitro incubation led to the formation of new apatite layers on the hydrogel surfaces. Cytotoxicity tests showed no significant adverse effects on L-929 fibroblasts. NF-κB activation suggested potential immune-modulating effects of the composites.

The study demonstrated that WPI/HAp hydrogels can form bioactive layers when exposed to simulated physiological fluids. The composites retained mechanical and structural integrity as HAp content increased. No cytotoxic effects were observed, suggesting biocompatibility with fibroblasts. The activation of NF-κB indicates a possible role in immune response modulation. These findings support the use of WPI/HAp composites as a novel bone substitute material. The materials showed promise for applications requiring both mechanical strength and bioactivity. The results align with the authors’ hypothesis that WPI can serve as an effective matrix for HAp. Further research is needed to confirm long-term performance in vivo.